More than 10 million people worldwide are suffering from Parkinson’s disease¹. The available therapies are largely symptomatic and there are no truly disease modifying treatment options available as yet that can protect the loss of dopamine producing neurons.

SCC - 138, is a potent, orally active, and exhibits superior safety / tolerability profile. In MPTP mouse model SCC - 138 protects the loss of the dopamine-producing neurons.

SPARC has completed two Phase 1 studies with no observed significant adverse events in both studies. The preliminary pharmacokinetic data indicate the presence of drug in the CSF, suggesting that the drug is able to get to its site of intended action.

We have initiated a Phase 2 Study (PROSEEK) to evaluate the efficacy, safety and tolerability of SCC-138 in subjects with early Parkinson's Disease (PD) who are not receiving dopaminergic therapy.

For more details on the PROSEEK study visit: www.proseekstudy.com